background
sever
fever
thrombocytopenia
syndrom
sft
acut
infecti
diseas
caus
sft
viru
character
high
case
fatal
rate
current
effect
therapi
diseas
administr
ribavirin
improv
case
fatal
rate
viral
load
patient
blood
inhibit
viral
infect
vitro
method
vero
cell
pretreat
interferon
ifn
alon
combin
ribavirin
drug
inocul
sft
viru
three
day
later
supernat
harvest
subject
viru
titrat
unpair
ttest
use
statist
analysi
drug
effect
result
effect
high
concentr
slightli
weaker
ifn
ifn
show
dosedepend
inhibitori
effect
combin
usag
ifn
ribavirin
effect
concentr
show
larg
inhibitori
effect
log
reduct
viral
titer
combin
usag
one
typeiii
ifn
ribavirin
drastic
reduc
sft
viru
infect
therefor
may
use
treatment
sft
sever
fever
thrombocytopenia
syndrom
sft
recentlyidentifi
tickborn
infecti
diseas
character
fever
gastrointestin
symptom
thrombocytopaenia
leukopaenia
elev
level
liver
enzym
peripher
blood
multipl
organ
failur
neurolog
manifest
often
observ
sever
case
case
fatal
rate
caus
agent
diseas
sft
viru
famili
bunyavirida
genu
phleboviru
discoveri
report
current
vaccin
therapi
drug
proven
effect
diseas
report
sft
patient
treat
ribavirin
plasma
exchang
antibiot
steroid
recov
howev
report
deem
inconclus
none
treatment
tri
suffici
number
patient
liu
et
al
report
effect
ribavirin
guanosin
analogu
broad
antivir
activ
treatment
total
patient
roughli
half
receiv
ribavirin
studi
daili
intraven
inject
mg
ribavirin
significantli
affect
case
fatal
rate
platelet
count
viral
load
blood
indic
ribavirin
effect
sft
dose
howev
ribavirin
appar
show
antisft
viru
effect
vitro
thu
higher
dose
ribavirin
differ
drugstrategi
like
necessari
treatment
sft
present
studi
examin
effect
interferon
ifn
alon
combin
ribavirin
sft
viru
infect
vitro
combin
usag
ifn
ribavirin
show
larg
inhibitori
effect
suggest
usabl
sft
treatment
viral
titer
obtain
vero
cell
inocul
absencepres
indic
concentr
ifn
shown
fig
although
statist
signific
inhibitori
effect
observ
uml
ngml
reduct
viral
titer
lower
especi
higher
concentr
fig
b
c
reduct
curv
use
calcul
effect
concentr
ec
ec
drug
concentr
viral
titer
logreduc
respect
ec
valu
uml
uml
ngml
respect
ec
valu
uml
uml
ngml
respect
cytotox
examin
measur
cell
viabil
cell
cultur
presenc
drug
without
viru
inocul
shown
fig
viabil
maintain
examin
concentr
fig
b
ngml
cell
viabil
reduc
fig
find
indic
except
high
concentr
ngml
reduc
titer
sft
viru
presenc
ifn
fig
use
reduct
curv
alreadi
report
fig
ec
ribavirin
inhibit
sft
viru
infect
calcul
combin
effect
ifn
ribavirin
result
mean
standard
deviat
obtain
three
independ
experi
n
measur
cytotox
ifn
viabil
vero
cell
cultur
presenc
b
c
measur
use
reagent
cell
viabil
calcul
follow
absorb
cell
presenc
drugabsorb
cell
presenc
drug
absorb
cell
absenc
drugabsorb
cell
absenc
drug
experi
perform
triplic
mean
standard
deviat
n
shown
red
effect
cytotox
ribavirin
calcul
data
report
previous
make
comparison
ifn
easi
statist
analysi
unpair
ttest
comparison
data
drug
perform
data
antisft
viru
effect
ifn
ribavirin
p
p
examin
concentr
respect
ec
valu
time
singl
effect
drug
also
examin
fig
expect
use
alon
drug
show
nearli
reduct
viral
titer
ec
log
log
log
ribavirin
log
viral
titer
greatli
reduc
combin
usag
log
log
log
differ
effect
combin
usag
singl
usag
statist
signific
p
unpair
ttest
combin
effect
reduct
viral
titer
also
examin
among
three
ifn
log
log
log
result
tripl
quadrupl
combin
ifn
ribavirin
show
greater
inhibitori
effect
sft
viru
infect
singleor
doublecombinationusag
drug
indic
fig
examin
cytotox
combin
effect
studi
reveal
viabil
maintain
combin
fig
combin
show
statist
signific
differ
comparison
control
drug
unpair
ttest
combin
usag
two
drug
drastic
reduc
growth
hepat
c
viru
human
immunodefici
viru
hiv
vitro
improv
treatment
diseas
treatment
hepat
c
initi
drug
combin
broadspectrum
antivir
agent
ifn
ribavirin
treatment
shift
combin
ifn
specif
antivir
drug
drug
combin
specif
antivir
drug
hiv
initi
effici
combin
treatment
hivspecif
drugsin
princip
chang
even
recent
treatment
regimen
specif
antivir
yet
develop
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
mer
coronavirus
combin
ifn
ribavirin
shown
effect
vitro
vivo
experi
case
mer
treatment
patient
present
studi
singl
usag
ribavirin
ifn
shown
significantli
reduc
growth
sft
viru
furthermor
shown
combin
usag
drug
low
dosag
result
larg
inhibitori
effect
vitro
use
singularli
exampl
approxim
ribavirin
uml
uml
ml
necessari
achiev
reduct
viral
growth
contrast
combin
ribavirin
either
uml
uml
ngml
result
reduct
viral
growth
ribavirin
concentr
blood
might
achiev
human
drug
reach
peak
serum
concentr
dose
high
mg
inject
intraven
howev
present
studi
use
vero
cell
higher
concentr
ribavirin
requir
inhibit
growth
sft
viru
mani
virus
cell
type
probabl
due
insuffici
phosphoryl
ribavirin
activ
triphosph
form
cell
line
therefor
administr
high
ribavirin
dose
mg
might
show
larg
inhibitori
effect
sft
viru
combin
ifn
although
ifn
use
present
studi
researchuseonli
concentr
u
ml
observ
intraven
inject
u
humanuseapprov
ifn
fig
concentr
drug
use
ribavirin
uml
uml
ngml
ec
drug
inhibit
sft
viru
infect
experi
perform
triplic
mean
standard
deviat
shown
n
p
p
unpair
ttest
comparison
data
drug
time
higher
ifn
concentr
requir
reach
ec
sft
viru
vitro
thu
combin
usag
ribavirin
ifn
accept
dosag
might
result
larg
reduct
sft
viru
infect
vivo
could
therefor
effect
therapi
treatment
sft
patient
sft
viru
shown
suppress
cellular
ifn
respons
treatment
patient
drug
includ
ifn
perhap
initi
soon
diagnosi
sft
done
comparison
combin
effect
singl
ifn
ribavirin
respect
ec
combin
effect
ifn
without
ribavirin
sft
viru
infect
especi
effect
small
howev
small
combin
effect
among
ifn
expect
due
follow
reason
although
precis
mechan
ribavirin
affect
sft
viru
replic
unclear
ribavirin
ifn
like
work
independ
ii
typei
ifn
complet
share
receptor
transduc
intracellular
signal
iii
typeii
ifn
partial
share
molecul
signal
transduct
typei
ifn
result
howev
strongli
suggest
drug
inhibit
sft
viru
prolifer
mechan
differ
ifnsribavirin
could
candid
drug
use
combin
ifnsribavirin
treatment
sft
patient
studi
may
elucid
sft
virusspecif
inhibitor
andor
neutral
antibodi
sft
therapi
combin
usag
one
type
iii
ifn
ribavirin
drastic
reduc
sft
viru
infect
therefor
may
use
treatment
sft
monkey
kidneyderiv
vero
cell
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
heatinactiv
fetal
calf
serum
fc
sigma
antibiot
pen
strep
gibco
isol
japanes
sft
viru
strain
report
viru
titrat
perform
describ
previous
ribavirin
provid
yamasashouyu
co
ltd
choshi
japan
dissolv
phosphatebuff
salin
concentr
mgml
univers
type
ifn
pbl
interferonsourc
human
ifn
beta
pbl
interferonsourc
r
system
dissolv
dmem
supplement
fc
uml
uml
respect
treatment
cell
drug
dilut
cell
cultur
medium
indic
concentr
alon
indic
combin
cell
pretreat
drug
indic
concentr
h
one
hundr
tcid
sft
viru
ad
cultur
without
remov
drug
cultur
day
cultur
supernat
harvest
subject
viru
titrat
cytotox
drug
vero
cell
measur
describ
previous
cell
cultur
day
presenc
absenc
drug
without
viru
inocul
cell
viabil
measur
use
cell
prolifer
reagent
roch
accord
manufactur
protocol
cell
viabil
calcul
follow
absorb
cell
presenc
drug
absorb
cell
presenc
drug
absorb
cell
absenc
drug
absorb
cell
absenc
drug
unpair
ttest
use
statist
analysi
drug
effect
